<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00239798</url>
  </required_header>
  <id_info>
    <org_study_id>CFTY720A2218E1</org_study_id>
    <nct_id>NCT00239798</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients</brief_title>
  <official_title>A 24-month Extension of a One-year, Multicenter, Double Blinded Double Dummy, Randomized Study to Evaluate the Safety and Efficacy of Two Doses of FTY720 Combined With Full-dose Cyclosporine, USP [Modified] (Novartis Brand) and Steroids Versus Mycophenolate Mofetil Combined With Full-dose Cyclosporine, USP [Modified] (Novartis Brand) and Steroids, in Adult de Novo Renal Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of FTY720 combined with cyclosporine and
      corticosteroids in patients receiving a kidney transplant.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IA, IB, IIA, IIB, III, or humoral acute rejection diagnosed by biopsy according to Banff 97 criteria within 36 months post transplant</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Permanent resumption of dialysis within 36 months post transplant</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Surgical removal of graft within 36 months post transplant</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Death within 36 months post transplant</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Withdrawal of consent, death, or lost to follow up within 36 months post transplant</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum creatinine, and estimated creatinine clearance within 36 months post transplant</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>FEV1 , FVC, FEV1/FVC, DLCO and FEF 25%-75% within 36 months post transplant</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute lymphocyte count within 36 months post transplant</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>IA, IB, IIA, IIB, III, or humoral rejection diagnosed by biopsy according to Banff 97 criteria at Month 24 and Month 36 post-transplant</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Permanent resumption of dialysis at Month 24 and Month 36 post-transplant</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical removal of graft at Month 24 and Month 36 post-transplant</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death at Month 24 and Month 36 post-transplant</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Withdrawal of consent, death, or lost to follow up at Month 24 and Month 36 post-transplant</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine, and estimated creatinine clearance at Month 24 and Month 36 post-transplant</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 , FVC, FEV1/FVC, DLCO and FEF 25%-75% at Month 24 and Month 36 post-transplant</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute lymphocyte count at Month 18, 24, 30 and 36</measure>
  </secondary_outcome>
  <enrollment>255</enrollment>
  <condition>Renal Transplantation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FTY720</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Patients who have completed the 12 Month visit of the Core trial either on or off
             study drug.

          -  Female capable of becoming pregnant are required to have a medically approved method
             of birth control until 3 Month after study medication was stopped.

        Exclusion Criteria

        - None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Study Director</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2372</url>
    <description>Results for CFTY720A2218E1 from Novartis Clinical Trials Website</description>
  </link>
  <results_reference>
    <citation>Tedesco-Silva H, Szakaly P, Shoker A, Sommerer C, Yoshimura N, Schena FP, Cremer M, Hmissi A, Mayer H, Lang P; FTY720 2218 Clinical Study Group. FTY720 versus mycophenolate mofetil in de novo renal transplantation: six-month results of a double-blind study. Transplantation. 2007 Oct 15;84(7):885-92.</citation>
    <PMID>17984842</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2005</study_first_submitted>
  <study_first_submitted_qc>October 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2005</study_first_posted>
  <last_update_submitted>February 21, 2017</last_update_submitted>
  <last_update_submitted_qc>February 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transplantation, kidney, organ transplant</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fingolimod Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

